Unemployed women who begin taking GLP-1 weight-loss medications like Ozempic or Wegovy experience a 27% increase in their employment rate within 18 months, according to a working paper from the National Bureau of Economic Research (NBER). Harvard economist Rebecca Diamond, who analyzed survey data from over 10,000 adults, found that these gains appear tied to initial hiring impressions rather than long-term career advancement.
How GLP-1 Use Affects Hiring Outcomes
The NBER research highlights a distinct correlation between the use of weight-loss drugs and improved labor market outcomes for women. According to the study, women who successfully accessed these medications saw a significant boost in employment compared to a control group of women who desired the drugs but had not yet secured them.
Diamond’s analysis suggests the advantage is concentrated at the point of entry. Once women were already employed, the data showed little change in their pay or job mobility. This indicates that the primary driver for these employment gains is likely the mitigation of weight bias during the hiring process, rather than a direct change in workplace performance or professional development.
The study also observed social impacts beyond the workplace. Single women were found to be 29% more likely to enter into a marriage or cohabitation arrangement within 18 months of starting GLP-1 medications.
Does Weight Bias Shape Economic Inequality?
The findings raise significant questions regarding how medication access may influence existing socioeconomic disparities. As reported by Business Insider, the study—which has not yet undergone peer review—suggests that the benefits of GLP-1 usage could exacerbate inequality.
Wealthier individuals who can afford to pay for these medications out-of-pocket may secure an advantage in both the labor and marriage markets. Because these markets carry inherent financial benefits, the ability to access these drugs could create a cycle where those with higher initial wealth see further economic gains, potentially widening the gap between different demographic groups.
Comparing Employment and Social Trends
While the NBER paper focuses on the 27% rise in employment for women, the data also provides a parallel look at personal milestones.
| Outcome | Increase (18-Month Period) |
|---|---|
| Employment Rate (Unemployed Women) | 27% |
| Marriage or Cohabitation | 29% |
As noted by Fast Company, the consistency between professional and personal life markers suggests that the social perception of weight—and the subsequent use of medical intervention to change it—plays a role in both hiring and partnership acquisition.
Frequently Asked Questions
Is this study peer-reviewed?
No, the NBER working paper mentioned has not yet undergone the formal peer-review process, as reported by Business Insider.
Did the study find changes for already employed women?
No. Rebecca Diamond noted that women who were already employed saw little change in their salary or ability to move up the career ladder after starting the medication.
What medications were included in the research?
The analysis focused on GLP-1 receptor agonists, specifically citing Ozempic and Wegovy.
What are your thoughts on the intersection of medical intervention and workplace dynamics? Share your perspective in the comments section below or subscribe to our newsletter for more updates on economic research and labor market trends.
